According to the report "The Global Use of Medicines 2022", prepared by the consulting firm IQVIA, the loss of patent protection will have an impact of more than 33.000 million euros in the next five years in the five largest European markets (Germany, France, Italy, Spain and United Kingdom). A report from the newspaper "El Economista" highlights the opportunity to improve efficiency and health sustainability offered by biosimilar medicines.